Acute toxicity and effectiveness of idarubicin in childhood acute lymphoblastic leukemia

European Journal of Haematology

Volumn 58, Issue 5, 1997, Pages 326-332

  Neuendank, Andrea ^a   Hartmann, Reinhard ^a   Bührer, Christoph ^a   Winterhalter, Bernd ^b   Klumper, Edwin ^c   Veerman, Anjo J P ^c   Henze, Günter ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b PFIZER INC   (United States)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Acute lymphoblastic leukemia; Drug resistance; Idarubicin; Phase II study

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTHRACYCLINE ANTIBIOTIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; IDARUBICIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BLAST CELL; BLOOD TOXICITY; BONE MARROW BIOPSY; CARDIOTOXICITY; CHILD; CHILDHOOD LEUKEMIA; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; STOMATITIS;

EID: 0030743164     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1997.tb01679.x     Document Type: Article

References (47)

1. HENZE G, FENGLER R, HARTMANN R, et al. Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM Group. Blood 1991: 78: 1166-1172.
2. PUI CH, CRIST WM. Biology and treatment of acute lymphoblastic leukemia. J Pediatr 1994: 124: 491-503.
3. BERMAN E. New drugs in acute myelogenous leukemia: a review. J Clin Pharmacol 1992: 32: 296-309.
4. CARELLA AM, CARLIER P, PUNGOLINO E, et al. Idarubicin in combination with intermediate-dose cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia. Leukemia 1993: 7: 196-199.
5. KUSNIERZ-GLAZ CR, NORMANN D, WEINBERG R, et al. Subcutaneous low dose arabinosyl-cytosine and oral idarubicin in high risk adult acute myelogenous leukemia. Hematol Oncol 1993: 11: 73-80.
6. PHILPOTT N, MEHTA J, TRELEAVEN J, POWLES R. Idarubicin, high-dose cytarabine and etoposide for remission induction in therapy-related acute myeloid leukemia. Leuk Lymph 1994: 15: 127-130.
7. SACKMANN-MURIEL F, FERNANDEZ-BARBIERI MA, SANTARELLI MT, et al. Results of treatment with an intensive combination induction regimen containing idarubicin in children with acute myeloblastic leukemia: preliminary report of the Argentine Group for Treatment of Acute Leukemia. Semin Oncol 1993: 20 (Suppl 8): 34-38.
8. VOGLER WR, VELEZ-GARCIA E, WEINER RS, et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia. J Clin Oncol 1992: 10: 1103-1111.
9. CARELLA AM, BERMAN E, MARAONE MP, GANZINA F. Idarubicin in the treatment of acute leukemias. An overview of preclinical and clinical studies. Haematologica 1990: 75: 159-169.
10. ERTTMANN R, BODE U, ERB N, et al. Antineoplastic effectiveness and toxicity of idarubicin (4-demethoxydaunorubicin) in refractory acute leukemia in childhood. Klin Padiatr 1988: 200: 200-204.
11. GIONA F, TESTI AM, AMADORI S, et al. Idarubicin and high-dose cytarabine in the treatment of refractory and relapsed acute lymphoblastic leukemia. Ann Oncol 1990: 1: 51-55.
12. GIONA F, TESTI AM, ANNINO L, et al. Treatment of primary refractory and relapsed acute lymphoblastic leukaemia in children and adults: the GIMEMA/AIEOP experience. Br J Haematol 1994: 86: 55-61.
13. MADON E, GRAZIA G, DEBERNARDI B, et al. Phase II study of idarubicin administered IV to pediatric patients with acute lymphoblastic leukemia. Cancer Treat Rep 1987: 71: 855-856.
14. TESTI AM, MOLETI ML, GIONA F, et al. Treatment of primary refractory or relapsed acute lymphoblastic leukemia (ALL) in children. Ann Oncol 1992: 3: 765-767.
15. CARELLA AM, PUNGOLINO E, PIATTI G, et al. Idarubicin in combination with intermediate-dose cytarabine in the treatment of refractory or relapsed acute leukemias. Eur J Haematol 1989: 43: 309-313.
16. CAVANNA L, DISTASI M, FORNARI F, et al. Idarubicin plus attenuated high-dose cytosine arabinoside in the treatment of relapsed and refractory leukemia (letter). Eur J Haematol 1990: 45: 180-181.
17. PUI CH, DEGRAAF SS, DOW LW, et al. Phase I clinical trial of orally administered 4-demethoxydaunorubicin (idarubicin) with pharmacokinetic and in vitro drug sensitivity testing in children with refractory leukemia. Cancer Res 1988: 48: 5348-5352.
18. LEGHA SS, BENJAMIN RS, MACKAY B, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982: 96: 133-139.
19. LUDWIG WD, RAGHAVACHAR A, THIEL E. Immunophenotypic classification of acute lymphoblastic leukaemia. Baillières Clin Haematol 1994: 7: 235-262.
20. PIETERS R, LOONEN AH, HUISMANS DR, et al. In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions. Blood 1990: 76: 2327-2336.
21. HITCHCOCK-BRYAN S, GELBER R, CASSADY JR, SALLAN SE. The impact of induction anthracycline on long-term failure-free survival in childhood acute lymphoblastic leukemia. Med Pediatr Oncol 1986: 14: 211-215.
22. MINDERMAN H, BUSCAGLIA MD, RUSTUM YM. Schedule-dependent efficacy of idarubicin (Ida) and doxorubicin (Dox). Leukemia 1994: 8: 1401-1405.
23. ROBERT J, RIGAL-HUGUET F, HURTELOUP P. Comparative pharmacokinetic study of idarubicin and daunorubicin in leukemia patients. Hematol Oncol 1992: 10: 111-116.
24. TIDEFELT U, SUNDMAN-ENGBERG B, PAUL C. Comparison of the intracellular pharmacokinetics of daunorubicin and idarubicin in patients with acute leukemia. Leuk Res 1994: 18: 293-297.
25. AMES MM, SPREAFICO F. Selected pharmacologie characteristics of idarubicin and idarubicinol. Leukemia 1992: 6 (Suppl 1): 70-75.
26. KUFFEL MJ, REID JM, AMES MM. Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture. Cancer Chemother Pharmacol 1992: 30: 51-57.
27. REID JM, PENDERGRASS TW, KRAILO MD, HAMMOND GD, AMES MM. Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Childrens Cancer Study Group report. Cancer Res 1990: 50: 6525-6528.
28. AVVISATI G, MANDELLI F, PETTI MC, et al. Idarubicin (4-demethoxydaunorubicin) as single agent for remission induction of previously untreated acute promyelocytic leukemia: a pilot study of the Italian cooperative group GIMEMA. Eur J Haematol 1990: 44: 257-260.
29. CASAZZA AM. Experimental evaluation of anthracycline analogs. Cancer Treat Rep 1979: 63: 835-844.
30. FEIG SA, KRAILO MD, HARRIS RE, et al. Determination of the maximum tolerated dose of idarubicin when used in a combination chemotherapy program of reinduction of childhood ALL at first marrow relapse and a preliminary assessment of toxicity compared to that of daunorubicin: a report from the Childrens Cancer Study Group. Med Pediatr Oncol 1992: 20: 124-129.
31. ZANETTE L, ZUCHETTI M, FRESHI A, ERRANTI D, TIRELLI U, D'INCALCI M. Pharmacokinetics of 4-demethoxydaunorubicin in cancer patients. Cancer Chemother Pharmacol 1990: 25: 445-448.
32. GOEBEL M, KAPLAN E. Anthracycline-induced cardiotoxicity - a review. Onkologie 1992: 15: 198-204.
33. YEUNG ST, YOONG C, SPINK J, GALBRAITH A, SMITH PJ. Functional myocardial impairment in children treated with anthracyclines for cancer. Lancet 1991: 337: 816-818.
34. CERSOSIMO RJ. Idarubicin: an anthracycline antineoplastic agent. Clin Pharm 1992: 11: 152-167.
35. FUKUSHIMA T, KAWAI Y, URASAKI Y, YOSHIDA A, UEDA T, NAKAMURA T. Influence of idarubicinol on the antileukemic effect of idarubicin. Leuk Res 1994: 18: 943-947.
36. ERTTMANN R, ERB N, FORCADELL DEDIOS P, NEURATH C, LOOFT G, LANDBECK G. Uptake of anthracyclines into sensitive and resistant leukemic cells. Klin Padiatr 1989: 201: 40-45.
37. STEINHERZ PG, REDNER A, STEINHERZ L, MEYERS P, TAN C, HELLER G. Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse. The Memorial Sloan-Kettering-New York-II protocol. Cancer 1993: 72: 3120-3130.
38. LIPSHULTZ SE, LIPSITZ SR, MONE SM, et al. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995: 332: 1738-1743.
39. GOORIN AM, CHAUVENET AR, PEREZ-ATAYDE AR, CRUZ J, MCKONE R, LIPSHULTZ SE. Initial congestive heart failure, six to ten years after doxorubicin chemotherapy for childhood cancer. J Pediatr 1990: 116: 144-147.
40. LARSEN RL, JAKACKI RI, VETTER VL, MEADOWS AT, SILBER JH, BARBER G. Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults. Am J Cardiol 1992: 70: 73-77.
41. LIPSHULTZ SE, COLAN SD, GELBER RD, PEREZ-ATAYDE AR, SALLAN SE, SANDERS SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991: 324: 808-815.
42. KLUMPER E, PIETERS R, VEERMAN AJ, et al. In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia. Blood 1995: 86: 3861-3868.
43. BERMAN E, MCBRIDE M. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemic cells. Blood 1992: 79: 3267-3273.
44. MICHIELI M, MICHELUTTI A, DAMIANI D, et al. A comparative analysis of the sensitivity of multidrug resistant (MDR) and non-MDR cells to different anthracycline derivatives. Leuk Lymph 1993: 9: 255-264.
45. MINDERMAN H, LINSSEN P, VANDERLELY N, et al. Toxicity of idarubicin and doxorubicin towards normal and leukemic human bone marrow progenitors in relation to their proliferative state. Leukemia 1994: 8: 382-387.
46. KLUMPER E, PIETERS R, DENBOER ML, HUISMANS DR, LOONEN AH, VEERMAN AJ. In vitro anthracycline cross-resistance pattern in childhood acute lymphoblastic leukaemia. Br J Cancer 1995: 71: 1188-1193.
47. PIETERS R, KASPERS GJ, KLUMPER E, VEERMAN AJ. Clinical relevance of in vitro drug resistance testing in childhood acute lymphoblastic leukemia: the state of art. Med Pediatr Oncol 1994: 22: 299-308.